Bone turnover markers: basic biology to clinical applications

M Schini, T Vilaca, F Gossiel, S Salam… - Endocrine …, 2023 - academic.oup.com
Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the
last 20 years, much experience has been gained in measurement and interpretation of these …

Chronic kidney disease—mineral and bone disorders: pathogenesis and management

JB Cannata-Andía, B Martín-Carro… - Calcified tissue …, 2021 - Springer
The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …

Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes …

M Ketteler, GA Block, P Evenepoel… - Annals of internal …, 2018 - acpjournals.org
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical
Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of …

KDOQI clinical practice guideline for nutrition in CKD: 2020 update

TA Ikizler, JD Burrowes, LD Byham-Gray… - American Journal of …, 2020 - Elsevier
Abstract The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
(KDOQI) has provided evidence-based guidelines for nutrition in kidney diseases since …

Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update

R Vanholder, A Pletinck, E Schepers, G Glorieux - Toxins, 2018 - mdpi.com
In this narrative review, the biological/biochemical impact (toxicity) of a large array of known
individual uremic retention solutes and groups of solutes is summarized. We classified these …

Osteoporosis in patients with chronic kidney diseases: a systemic review

CY Hsu, LR Chen, KH Chen - International journal of molecular sciences, 2020 - mdpi.com
Chronic kidney disease (CKD) is associated with the development of mineral bone disorder
(MBD), osteoporosis, and fragility fractures. Among CKD patients, adynamic bone disease or …

Parathyroidectomy in the management of secondary hyperparathyroidism

WL Lau, Y Obi, K Kalantar-Zadeh - Clinical Journal of the …, 2018 - journals.lww.com
Secondary hyperparathyroidism develops in CKD due to a combination of vitamin D
deficiency, hypocalcemia, and hyperphosphatemia, and it exists in nearly all patients at the …

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

EVOLVE Trial Investigators - New England Journal of Medicine, 2012 - Mass Medical Soc
Background Disorders of mineral metabolism, including secondary hyperparathyroidism, are
thought to contribute to extraskeletal (including vascular) calcification among patients with …

Mineral bone disorders in kidney disease patients: the ever-current topic

L Hu, A Napoletano, M Provenzano, C Garofalo… - International Journal of …, 2022 - mdpi.com
Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most
prevalent worldwide. Chronic kidney disease–mineral bone disorders (CKD–MBD) with …

Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS …

F Tentori, M Wang, BA Bieber… - Clinical Journal of the …, 2015 - journals.lww.com
Results Median parathyroid hormone increased from phase 1 to phase 4 in all regions
except for Japan, where it remained stable. Prescriptions of intravenous vitamin D analogs …